MyFinsight
Home
Blog
About
Contact
Download
Download image
Unrealized gain (loss) on
investment securities
$1,074K
(7771.43%↑ Y/Y)
Comprehensive loss
-$464,415K
(-55.62%↓ Y/Y)
Total other
comprehensive income (loss)
$902K
Unrealized loss on foreign
currency
-$172K
Net loss
-$465,317K
(-55.93%↓ Y/Y)
Loss before equity
method investment
-$465,317K
(-256.18%↓ Y/Y)
Interest income
$51,989K
(25.47%↑ Y/Y)
Loss before income
taxes
-$465,137K
Income tax expense
$180K
Total other income,
net
$51,632K
(26.19%↑ Y/Y)
Product
$5,420K
License And Service
$2,276K
Other expense, net
-$357K
Loss from operations
-$516,769K
(-52.50%↓ Y/Y)
Total revenue, net
$7,696K
(640.71%↑ Y/Y)
Total operating
expenses
$524,465K
(54.30%↑ Y/Y)
Research and development
$332,058K
(38.27%↑ Y/Y)
Selling, general and
administrative
$191,331K
Cost of product
revenue
$1,076K
Back
Back
Income Statement
source: myfinsight.com
Crinetics Pharmaceuticals, Inc. (CRNX)
Crinetics Pharmaceuticals, Inc. (CRNX)